Oxytetracycline belongs to a structurally diverse class of aromatic
polyketide antibiotics, also known as bacterial aromatic polyketides, produced by
Streptomyces via type II
polyketide synthases (PKSs). Other compounds produced via type II PKSs are important bioactive compounds ranging from anticancer agents like
doxorubicin to antibiotics such as
tetracycline. The biosynthesis of oxytetracycline can be broken down into three general portions: to
catalyze the extension of the malonamyl-CoA starting unit with eight
malonyl-CoA extender units. The process of elongating the polypeptide skeleton occurs through a series of
Claisen-like
decarboxylation reactions until the linear tetracyclic skeleton is formed. Thus, minimal PKSs form a completed
amidated polyketide backbone without any additional post-synthase tailoring enzymes (Figure 1). Following the formation of the linear tetracyclic skeleton, four successive
cyclization reactions must occur in a
regioselective manner to produce the
aromatic natural product known as pretetramid, a common precursor to both oxytetracycline and other tetracycline antibiotics. In the oxytetracycline gene cluster, these enzymes are encoded as
OxyK (
aromatase),
OxyN (
cyclase), and
OxyI (cyclase). Formation of pretetramid allows for one of the most important intermediates en route to the biosynthesis of oxytetracycline; this is the generation of anhydrotetracycline. Anhydrotetracycline contains the first functionalized
A ring in this biosynthetic pathway. After the formation of anhydrotetracycline, ATC
monooxygenase (
OxyS)
oxidizes the C-6 position in an
enantioselective manner in the presence of the
cofactor NADPH and
atmospheric oxygen to produce 5a,11a-dehydrotetracycline. Next, a
hydroxylation occurs at the C-5 position of 5a,11a-dehydrotetracycline via the
oxygenase encoded as
OxyE in the oxytetracycline gene cluster. This produces the intermediate 5a,11a-dehydro-oxytetracycline. However, the exact mechanism of this step remains unclear. The final step of this biosynthesis occurs through the
reduction of a
double bond in the
α, β—unsaturated ketone of 5a,11a-dehydro-oxytetracycline. In this final step, the cofactor NADPH is employed by
TchA (
reductase) as the
reducing agent. Upon reduction, the
enol form is favored due to
conjugation, thus producing the aromatic polyketide oxytetracycline. Figure 2 shows the biosynthesis as described above, as well as an arrow-pushing mechanism of NADPH being used as the final cofactor in the biosynthesis of oxytetracycline. == Veterinary indications ==